Related Experiment Video
Updated: Mar 25, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Reduction in mitochondrial iron alleviates cardiac damage during injury
Hsiang-Chun Chang1, Rongxue Wu1, Meng Shang1
1Feinberg Cardiovascular Research Institute (FCVRI), Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract:
Excess cellular iron increases reactive oxygen species (ROS) production and causes cellular damage. Mitochondria are the major site of iron metabolism and ROS production; however, few studies have investigated the role of mitochondrial iron in the development of cardiac disorders, such as ischemic heart disease or cardiomyopathy (CM). We observe increased mitochondrial iron in mice after ischemia/reperfusion (I/R) and in human hearts with ischemic CM, and hypothesize that decreasing mitochondrial iron protects against I/R damage and the development of CM. Reducing mitochondrial iron genetically through cardiac-specific overexpression of a mitochondrial iron export protein or pharmacologically using a mitochondria-permeable iron chelator protects mice against I/R injury. Furthermore, decreasing mitochondrial iron protects the murine hearts in a model of spontaneous CM with mitochondrial iron accumulation. Reduced mitochondrial ROS that is independent of alterations in the electron transport chain's ROS producing capacity contributes to the protective effects. Overall, our findings suggest that mitochondrial iron contributes to cardiac ischemic damage, and may be a novel therapeutic target against ischemic heart disease.
Insights
Reducing mitochondrial iron protects the heart from damage. Lowering iron in heart mitochondria lessens reactive oxygen species (ROS) and guards against cardiac disorders like cardiomyopathy.
Area of Science:
- Cardiovascular Science
- Mitochondrial Biology
- Iron Metabolism
Background:
- Excess cellular iron elevates reactive oxygen species (ROS), leading to cellular damage.
- Mitochondria are central to iron metabolism and ROS generation, yet their role in cardiac disorders remains understudied.
- Mitochondrial iron accumulation is observed in cardiac conditions like ischemic cardiomyopathy.
Purpose of the Study:
- To investigate the role of mitochondrial iron in cardiac damage and disease.
- To determine if reducing mitochondrial iron offers protection against ischemia/reperfusion (I/R) injury and cardiomyopathy (CM).
Main Methods:
- Assessed mitochondrial iron levels in mouse models of I/R injury and human ischemic CM.
- Utilized genetic approaches (cardiac-specific overexpression of an iron exporter) and pharmacological agents (mitochondria-permeable iron chelator) to reduce mitochondrial iron.
- Evaluated cardiac protection in I/R and spontaneous CM models.
Main Results:
- Mitochondrial iron levels were elevated post-I/R in mice and in human ischemic CM hearts.
- Both genetic and pharmacological reduction of mitochondrial iron conferred protection against I/R injury.
- Decreased mitochondrial iron also protected against spontaneous CM associated with iron accumulation.
- Protective effects were linked to reduced mitochondrial ROS, independent of electron transport chain capacity.
Conclusions:
- Mitochondrial iron accumulation is a significant factor in cardiac ischemic damage.
- Targeting mitochondrial iron represents a potential novel therapeutic strategy for ischemic heart disease.
- Reducing mitochondrial iron and associated ROS may prevent or treat cardiac dysfunction.
More Related Videos
07:14A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
